WT1 and acute myeloid leukemia: Table 4 depicts the FAB classification in relation to low and high expression for WT-1, BAALC and ERG. The results showed that, all patients in subtype M3 had high expression of WT-1. Also, in subtype M2, 67% of the patients showed high expression of WT-1. However, there were no significant differences among subtypes of AML in terms of WT-1 expression (P =0.08).